[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY30582A1 - Derivados de acido 2-fenoxinicotinico y su uso - Google Patents

Derivados de acido 2-fenoxinicotinico y su uso

Info

Publication number
UY30582A1
UY30582A1 UY30582A UY30582A UY30582A1 UY 30582 A1 UY30582 A1 UY 30582A1 UY 30582 A UY30582 A UY 30582A UY 30582 A UY30582 A UY 30582A UY 30582 A1 UY30582 A1 UY 30582A1
Authority
UY
Uruguay
Prior art keywords
prophylaxis
derivatives
treatment
phenoxinicotinic
acid
Prior art date
Application number
UY30582A
Other languages
English (en)
Inventor
Dr Axel Kretschmer
Dr Arounarith Tuch
Dr Yolanda Cancho-Grande
Dr Peter Kolkhof
Dr Lars Baerfacker
Dr Heinrich Meier
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of UY30582A1 publication Critical patent/UY30582A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de los ácidos 2-fenoxi-6-fenil-nicotínico y 2-fenoxi-6-piridilnicotínico, a procedimientos para su preparacion, a su uso para el tratamiento y/o profilaxis de enfermedades así como a su uso para la preparacion de medicamentos para el tratamiento y/o profilaxis de enfermedades, preferiblemente para el tratamiento y/o profilaxis de enfermedades cardiovasculares, particularmente de dislipidemias, arteriosclerosis e insuficiencia cardiaca.
UY30582A 2006-09-12 2007-09-11 Derivados de acido 2-fenoxinicotinico y su uso UY30582A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006043520A DE102006043520A1 (de) 2006-09-12 2006-09-12 2-Phenoxynikotinsäure-Derivate und ihre Verwendung

Publications (1)

Publication Number Publication Date
UY30582A1 true UY30582A1 (es) 2008-05-02

Family

ID=38681456

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30582A UY30582A1 (es) 2006-09-12 2007-09-11 Derivados de acido 2-fenoxinicotinico y su uso

Country Status (11)

Country Link
US (1) US20100298221A1 (es)
EP (1) EP2066635A2 (es)
JP (1) JP2010507569A (es)
AR (1) AR062586A1 (es)
CA (1) CA2662879A1 (es)
CL (1) CL2007002637A1 (es)
DE (1) DE102006043520A1 (es)
PE (1) PE20081371A1 (es)
TW (1) TW200829553A (es)
UY (1) UY30582A1 (es)
WO (1) WO2008031501A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
WO2014144485A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
RU2015139731A (ru) 2013-03-15 2017-04-20 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения первичного склерозирующего холангита и воспалительного заболевания кишечника
US20220160726A1 (en) 2019-02-12 2022-05-26 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492784A4 (en) * 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung

Also Published As

Publication number Publication date
TW200829553A (en) 2008-07-16
WO2008031501A3 (de) 2011-04-14
EP2066635A2 (de) 2009-06-10
AR062586A1 (es) 2008-11-19
WO2008031501A2 (de) 2008-03-20
PE20081371A1 (es) 2008-10-16
JP2010507569A (ja) 2010-03-11
CL2007002637A1 (es) 2008-03-14
DE102006043520A1 (de) 2008-03-27
CA2662879A1 (en) 2008-03-20
US20100298221A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
UY32970A (es) Acidos 3-fenilpropionicos sustituidos y su uso
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
DOP2006000062A (es) Derivados de acido pirimidincarboxilico y su uso
CU24056B1 (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematológicas
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
CU23874B1 (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
ECSP077340A (es) Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa
ECSP10010494A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
UY30582A1 (es) Derivados de acido 2-fenoxinicotinico y su uso
CL2013002129A1 (es) Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras.
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
CU20130078A7 (es) Ácidos 1-bencicloalquilcarboxílicos sustituidos y su uso
DOP2009000093A (es) Dihidropirazolonas sustituídas para el tratamiento de enfermedades cardiovasculares y hematológicas
DOP2005000177A (es) Nuevos derivados de pirimidina y su uso
CU20100183A7 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170726